Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753717 | 0.86 | SOS1 (0.41) | SOS1SOS2 | |
| SCHEMBL1753687 | 0.84 | SOS1 (0.45) | SOS1SOS2 | |
| SCHEMBL23467579 | 0.82 | DRD4 (0.35) | SOS1SOS2 | |
| SCHEMBL1753643 | 0.82 | DRD4 (0.35) | SOS1SOS2 | |
| SCHEMBL17754047 | 0.81 | DRD4 (0.33) | SOS1SOS2NEK2 | |
| SCHEMBL16627547 | 0.81 | — | — | |
| SCHEMBL1753697 | 0.79 | — | — | |
| SCHEMBL27379150 | 0.79 | SOS1 (0.50) | SOS1SOS2 | |
| SCHEMBL24081996 | 0.79 | SOS1 (0.50) | SOS1SOS2 | |
| SCHEMBL25820321 | 0.78 | DRD4 (0.33) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130689-A1 | 2-FLUOROBIPHENYL-4-ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏普莱医药生物技术有限公司 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130690-A1 | ETHYLENEDIAMINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏普莱医药生物技术有限公司 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4289428-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | disclosed |
| WO-2019200100-A1 | PLADIENOLIDE DERIVATIVES AS SPLICEOSOME TARGETING AGENTS FOR TREATING CANCER | COOK ANDREW (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-2102208-B1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-23 | — | — | EP | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | SOS1 1209/4885SOS2 2235/4885NEK2 3835/4885 |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | SOS1 3478/4885SOS2 3637/4885NEK2 2711/4885 |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | SOS1 1295/4885SOS2 3181/4885NEK2 1294/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | SOS1 55/4885SOS2 88/4885NEK2 1197/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | SOS1 55/4885SOS2 88/4885NEK2 1197/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | SOS1 3478/4885SOS2 3637/4885NEK2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.